

ABIVAX Upcoming Events

2017 Financial Results to be announced on March 16, 2018

PARIS, Mar. 12, 2018, 8:30 pm. CET – ABIVAX (Euronext Paris: FR0012333284 – ABVX), a biotechnology company harnessing the immune system to develop a functional cure for HIV and treatments for inflammatory/autoimmune diseases and cancer, today announces that its senior management team will participate in upcoming events for investors and business development professionals.

- March 12-14, 2018: BIO-Europe Spring in Amsterdam
Prof. Hartmut Ehrlich, M.D., CEO ABIVAX, will give a corporate update presentation on ABIVAX on Tuesday, March 13 at 11:00 in room E105
- March 16, 2018: Full Year 2017 Financial Results
- March 19-20, 2018: BIO Asia International Conference in Tokyo
- April 8-10, 2018: H.C. Wainwright Global Life Sciences Conference in Monaco

About ABIVAX (www.abivax.com/en)

ABIVAX is mobilizing the body's natural immune machinery to treat patients with viral infections, autoimmune diseases and cancer. A clinical-stage company, ABIVAX leverages its antiviral and immune enhancing platforms to optimize candidates to cure HIV and treat inflammatory bowel diseases and liver cancer. ABIVAX is listed on Euronext compartment B (ISIN: FR0012333284 – Mnémo : ABVX). More information on the company is available at www.abivax.com.

Follow us on Twitter @ABIVAX_

Contacts:

ABIVAX
Finance
Didier Blondel
didier.blondel@abivax.com
+33 1 53 83 08 41

Press Relations France
ALIZE RP
Caroline Carmagnol/Aurore Gangloff
abivax@alizerp.com
+33 6 64 18 99 59

Investors Relations
LifeSci Advisors
Chris Maggos
chris@lifesciadvisors.com
+41 79 367 6254



Press Relations US
LifeSci Public Relations

Matt Middleman, M.D.

matt@lifescipublicrelations.com

+1 646 627 8384

Investors and Press Relations Germany

MC Services AG

Anne Hennecke

anne.hennecke@mc-services.eu

+49 211 529 252 22